Novel Cardiac Sarcomere Modulator, EDG-7500, in Hypertrophic Cardiomyopathy: Evaluating New Phase II Data from CIRRUS-HCM

Hypertrophic cardiomyopathy (HCM) is an inherited disease characterised by thickening of the left ventricular wall, which can lead to symptoms such as fatigue, exertional dyspnoea, and an increased risk of sudden cardiac death. The approval of the first targeted therapy (mavacamten, a cardiac myosin inhibitor [CMI]) to treat obstructive HCM (oHCM) has been a significant advance. However, there are still many therapeutic unmet needs, crucially the lack of an approved treatment for non-obstructive HCM (nHCM). Additionally, CMIs can cause decreases in LVEF that necessitates a resource-intensive dose-titration process. EDG-7500, a novel, selective cardiac sarcomere modulator, is currently in development for the treatment of HCM, and data from the 4-week portion of the Phase II CIRRUS-HCM study of EDG-7500 were presented at the Annual Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in May 2025. During the interviews conducted for the European Medical Journal (EMJ) in June 2025, the significance of these new data was discussed by Michelle Michels, Director of the Erasmus MC Center of Expertise for Inherited Cardiovascular Diseases, Rotterdam, the Netherlands; and Perry Elliott, Director of the Institute of Cardiovascular Science, University College London (UCL), and consultant cardiologist at St Bartholomew’s Hospital, London, UK. The experts reviewed the clinical findings of CIRRUS-HCM, highlighting key elements including diastolic benefits and preservation of systolic function, as well as mechanistic features and practicalities, which have the potential to differentiate EDG-7500 from current targeted therapies.